Natalizumab Completed Phase 4 Trials for Disseminated Sclerosis Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT03516526Towards Personalized Dosing of Natalizumab in Multiple Sclerosis